

Vukic Soskic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790471/publications.pdf>

Version: 2024-02-01

6
papers

47
citations

1937685

4
h-index

2053705

5
g-index

6
all docs

6
docs citations

6
times ranked

117
citing authors

#	ARTICLE	IF	CITATIONS
1	Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death. <i>Neuropharmacology</i> , 2013, 72, 224-235.	4.1	17
2	Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats. <i>Journal of Neurochemistry</i> , 2015, 135, 125-138.	3.9	15
3	Arylpiperazine Dopaminergic Ligands Protect Neuroblastoma Cells from Nitric Oxide (NO)-Induced Mitochondrial Damage and Apoptosis. <i>ChemMedChem</i> , 2012, 7, 495-508.	3.2	7
4	<i>N</i> -[2-(4-(piperazin-1-yl)ethyl)phenyl]arylamides with Dopamine D ₂ and 5-HT _{1A} Activity: Synthesis, Testing, and Molecular Modeling. <i>Archiv Der Pharmazie</i> , 2013, 346, 708-717.	4.1	4
5	Modeling of Dopamine D2 Receptor - Overview of 35-Year Evolution. <i>Current Medicinal Chemistry</i> , 2015, 22, 2972-2990.	2.4	4
6	Identification of NQO1 and ferrochelatase as interaction partners for neuroprotective <i>N</i> -[2-(4-phenylpiperazin-1-yl)ethyl]phenylarylamides. <i>Chemical Biology and Drug Design</i> , 2018, 90, 1393-1397.		